Literature DB >> 17855149

[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results.

A Johansson1, I Savitcheva, A Forsberg, H Engler, B Långström, A Nordberg, H Askmark.   

Abstract

[(11)C]-PIB positron emission tomography ([(11)C]-PIB PET) is a sensitive marker of amyloid in Alzheimer's disease (AD), but its specificity has not been fully evaluated. Vascular amyloid-beta deposition is common in Parkinson's disease (PD) and alpha-synuclein, the major component of the Lewy bodies in PD, forms amyloid fibrils. We investigated five apparently cognitively normal PD patients with [(11)C]-PIB PET. The results were compared to 16 patients with AD and six healthy controls from a previous study. [(11)C]-PIB retention was not significantly increased in our patients who all had early stage PD. Further studies of more advanced PD patients are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855149     DOI: 10.1016/j.parkreldis.2007.07.010

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  22 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

Review 2.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

3.  Whatever happened to Pittsburgh Compound-A?

Authors:  William E Klunk; Chester A Mathis
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

Review 4.  Update on amyloid imaging: from healthy aging to Alzheimer's disease.

Authors:  David A Wolk; William Klunk
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

Review 5.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.

Authors:  Lisa Mosconi; Valentina Berti; Lidia Glodzik; Alberto Pupi; Susan De Santi; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes.

Authors:  Kirk A Frey; Myria Petrou
Journal:  Clin Transl Imaging       Date:  2015-02-01

Review 7.  Development of positron emission tomography β-amyloid plaque imaging agents.

Authors:  Chester A Mathis; N Scott Mason; Brian J Lopresti; William E Klunk
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

8.  Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia.

Authors:  Myria Petrou; Nicolaas I Bohnen; Martijn L T M Müller; Robert A Koeppe; Roger L Albin; Kirk A Frey
Journal:  Neurology       Date:  2012-08-29       Impact factor: 9.910

Review 9.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

Review 10.  The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation.

Authors:  William E Klunk; Chester A Mathis
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.